The China Veterinary Contract Manufacturing & Research Market was valued at $62.7 Million in 2026 and projected to reach to $104.4 Million by 2031, representing a compound annual growth rate of 10.7%. China's veterinary contract manufacturing and research market is positioned for exceptional growth through 2031, driven by rising livestock production, expanding aquaculture industries, and growing pet ownership across urban centers.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
China's veterinary contract manufacturing and research market is growing at 10.7% CAGR, significantly outpacing the global rate of 7.7%, driven by increased domestic demand for animal health solutions and biotechnology advancement.
China's government investments in animal health infrastructure and biotechnology capabilities are accelerating market growth, positioning the country as a key hub for veterinary contract manufacturing and research services in Asia.
The market is valued at $62.7 million in 2026 and projected to reach $104.4 million by 2031, representing a 66.5% increase over five years and reflecting strong investor confidence in China's veterinary sector.
Increasing collaboration between Chinese pharmaceutical companies and veterinary contract manufacturers is expanding service offerings, including drug development, clinical trials, and manufacturing capabilities for animal health products.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | CDMO SERVICES (Service) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 7.7% from 2026 to 2031 |
| Largest Segment | CDMO SERVICES (Service) |
| Market Size Base Year (Billions) | ~USD 6.38 (2026) |
| Revenue Forecast (Billions) | ~USD 9.24 (2031) |
| Segments Covered | Service, Type |
2 segment dimensions are covered across the global market.
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| MID-SIZED/SPECIALTY ANIMAL HEALTH FIRMS | 20 | 22.2 | 24.7 | 27.4 | 30.5 | 33.9 | 37.6 | 41.8 | 11.1 |
| MULTINATIONAL ANIMAL HEALTH COMPANIES | 23.2 | 25.3 | 27.6 | 30.1 | 32.8 | 35.8 | 39 | 42.6 | 9.1 |
| START-UPS & VETERINARY BIOTECH FIRMS | 8.1 | 9.2 | 10.5 | 11.9 | 13.6 | 15.4 | 17.6 | 20 | 13.8 |
| TOTAL | 51.3 | 56.7 | 62.7 | 69.4 | 76.8 | 85 | 94.2 | 104.4 | 10.7 |
China's veterinary contract manufacturing and research market is valued at $62.7 million in 2026.
China's market is projected to reach $104.4 million by 2031, representing a 10.7% CAGR from 2026.
Growth in China is driven by increasing pet ownership, livestock modernization, government pharmaceutical innovation support, and expanding international partnerships.
China's 10.7% CAGR significantly exceeds the global average of 7.7%, reflecting stronger market dynamics and investment in veterinary healthcare.
China offers cost-competitive production, established pharmaceutical manufacturing infrastructure, and a strong position as a global supplier of active pharmaceutical ingredients and finished products.
This research study extensively utilized both primary and secondary sources. It involved analyzing various factors that influence the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and the strategies employed by key players.
This research study utilized a variety of comprehensive secondary sources, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings from various companies. Secondary research was employed to gather information crucial for an in-depth, technical, market-oriented, and commercial analysis of the veterinary contract manufacturing & research market. This approach also helped identify key players in the industry and allowed for classification and segmentation based on emerging trends at the most detailed level. Furthermore, significant developments about both market and technological perspectives were documented. A database of primary industry leaders was created as part of this secondary research.
In the primary research process, we interviewed a range of sources from both the supply and demand sides to gather qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development, and operations managers, as well as presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the veterinary contract manufacturing & research market. Primary sources from the demand side include R&D scientists and researchers in animal health companies, veterinary clinicians, and veterinary biotech firms developing veterinary therapeutics and technologies.

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product/service managers.
Note 3: Tiers are defined based on a company’s total revenue. As of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
The total size of the veterinary contract manufacturing & research market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

After arriving at the veterinary contract manufacturing & research market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and obtain precise statistics for all segments and subsegments.
The veterinary contract research organization (CRO) market comprises third-party service providers that support animal-health companies in the outsourced research and development of veterinary pharmaceuticals, biologics, vaccines, and related products. Veterinary CROs provide services across the product lifecycle, including discovery support, preclinical studies, target animal safety, clinical field trials, bioequivalence studies, regulatory consulting, and post-approval research, in compliance with veterinary regulatory standards. These services are primarily used by animal-health pharmaceutical companies, biotechnology firms, and vaccine developers to reduce development timelines, access specialized expertise, manage regulatory complexity, and optimize R&D costs without maintaining a complete in-house research infrastructure. The veterinary contract development and manufacturing organization (CDMO) market consists of third-party manufacturers that provide outsourced development, scale-up, and commercial manufacturing services for veterinary drugs, biologics, vaccines, and related products. Veterinary CDMOs support animal-health companies through process and formulation development, API and finished dosage form manufacturing, fill-finish operations, packaging and labeling, quality control, stability testing, and regulatory manufacturing support, operating in accordance with veterinary GMP and biologics regulations.
These services enable animal-health companies to outsource capital-intensive manufacturing activities, increase production flexibility, manage capacity constraints, and accelerate market entry, particularly for complex formulations, sterile injectables, and veterinary vaccines.
With the given market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
Company InformationGeographic Analysis
Full forecast, segment splits, and company analysis for all Veterinary Contract Manufacturing & Research Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report